More patients are living with multiple chronic conditions with high rates of hepatitis C
Healthcare professionals are seeing an increase in the number of patients living with hepatitis C who are uninsured and cannot afford their medications. Chronic hepatitis C can progress more rapidly in individuals with an HIV-infection. In fact, the CDC estimates that approximately one quarter of those living with HIV/AIDS are living with the hepatitis C virus. Co-infection with these two viruses can result in poor health outcomes, treatment complications, and a faster progression to liver disease. A recent study presented at IDWeek suggests that since 2011, hepatitis C is the highest recorded condition for mortality.*
Medical experts agree that access to treatment is necessary for all patients living with hepatitis C, including more vulnerable populations. As a proven and trusted model for the HIV/AIDS community, HarborPath has expanded its portal to now offer healthcare professionals access to Merck's Zepatier for their uninsured patients living with hepatitis C.
HarborPath is collaborating with Quest Diagnostics to provide the HCV NS5A RNA resistance test available for uninsured patients. To learn more click:
* Holmberg SD, et al. Abstract 1972. Presented at: IDWeek; Oct. 7-11, 2015; San Diego.
ADAP Waiting List Program
HarborPath administers the AIDS Drug Assistance Program (ADAP) Waiting List Program, in which patients who are on their state’s ADAP Waiting Lists receive antiretroviral medications donated by pharmaceutical manufacturers. Learn more about the HarborPath ADAP Waiting List Program and enroll your eligible patients living with HIV/AIDS.
This site is intended for healthcare professionals and patient advocates. If you are a patient CLICK HERE to learn more about HarborPath.